Baker Tilly Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Baker Tilly Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,931	Closed	-$398K	–	565
2023 Q1	$398K	Sell	3,931 -156	-4%	-$16.2K	0.04%	392
2022 Q4	$488K	Sell	4,087 -1,118	-21%	-$131K	0.06%	330
2022 Q3	$553K	Sell	5,205 -246	-5%	-$25K	0.08%	271
2022 Q2	$531K	Sell	5,451 -434	-7%	-$40.1K	0.07%	286
2022 Q1	$552K	Buy	5,885 +2,057	+54%	+$174K	0.06%	323
2021 Q4	$326K	Sell	3,828 -460	-11%	-$42.3K	0.04%	422
2021 Q3	$411K	Buy	4,288 +1,335	+45%	+$126K	0.05%	361
2021 Q2	$287K	Buy	2,953 +864	+41%	+$82.8K	0.05%	408
2021 Q1	$203K	Buy	+2,089	New	+$219K	0.04%	446

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Baker Tilly Wealth Management's NBIX Position: Q2 2023 in Review

Baker Tilly Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q2 2023, closing a stake of 3,931 shares — an estimated $398K sold.

Baker Tilly Wealth Management first reported a position in NBIX in Q1 2021 and held it in 9 quarters. The position peaked at $553K in Q3 2022. 456 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

Baker Tilly Wealth Management reported no remaining Neurocrine Biosciences position as of Q2 2023 after selling out during the quarter.
Baker Tilly Wealth Management sold 3,931 Neurocrine Biosciences shares in Q2 2023, an estimated $398K.
Baker Tilly Wealth Management first reported a position in Neurocrine Biosciences in Q1 2021 and held it in 9 quarters.
Baker Tilly Wealth Management's Neurocrine Biosciences position peaked at $553K in Q3 2022.
456 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on Baker Tilly Wealth Management's 13F filing for Q2 2023, filed 20 Jul 2023.